DIA Appoints Co-Chairs for 2016 EuroMeeting in Hamburg
The congress will be held at the Congress Center Hamburg (CCH) in Germany on 6 to 8 April 2016. For the first time, it will feature one or more sessions on medical writing.
Karl Broich, President of the Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte, BfArM) in Germany, and Kemal Malik, a member of the board of management at Bayer AG in Germany, will be the co-chairs of the 28th Drug Information Association (DIA) EuroMeeting.
The congress will be held at the Congress Center Hamburg (CCH) in Germany on 6 to 8 April 2016. For the first time, it will feature one or more sessions on medical writing.
The call for abstracts for presentations, full sessions and tutorials is open until 29 June. Applicants may submit more than one abstract, and they should cover innovation, clinical research, clinical trials, regulatory science, medical affairs, eHealth/big data, pharmacovigilance, lifecycle benefit/risk management, availability of medicinal products, globalization, medical devices and combination products, and health tech assessment.
According to a statement on the DIA web site, the main aim of the 2016 EuroMeeting will be “to provide a platform for experts from all relevant disciplines within the entire healthcare development and access process to debate and find solutions to some of the most pertinent challenges faced in an ever-evolving healthcare system - including the need to drive innovation.”
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
